REGULATORY

Allow Use of OOS Autologous Cell Products via PMD Act Amendment: FIRM

May 21, 2024

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Japan’s regenerative medicines association on May 16 called for amending the Pharmaceuticals and Medical Devices (PMD) Act to allow for the use of autologous cell-processed products made for therapeutic purposes even when they are out of specification or OOS. The…

To read the full story

Advisory Panel Backs Transfer of GMP Inspection Authority for New Generics to PMDA
November 5, 2024
Panel OKs Withdrawal Rule for Conditional Nod, 2-Year Extension for Pediatric Data Protection towards PMD Act Amendment
October 4, 2024
MHLW Panel to Draw Up Report by Year-End towards Amendment of PMD Act
February 13, 2024

REGULATORY

Council Floats 9.6% Growth Target for Japan’s On-Patent Drug Market
March 11, 2026
MHLW Approves Towa Generics for Revolade, Vimpat
March 11, 2026
Panel Clears Zolgensma Intrathecal Form to Expand Use in Older SMA Patients
March 10, 2026
Japan Approves MSD’s HIV Combo Idvynso
March 9, 2026
MHLW Updates Elective Care LLP List; Target Products Down Sharply to 776
March 9, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Elevidys Opens New Era for DMD Treatments Targeting the Underlying Cause

By Shinya Sato

Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…

COLUMN

The Strategic MSL: Beyond Data Delivery, It’s About Impact

By Philip Carrigan

I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…